Table 3.
Anti-BCMA Therapies
| Agent | Target | Dose and Schedule | Efficacy Data | Adverse Events of Interest | |
|---|---|---|---|---|---|
| CAR T-Cell Therapies | Idecabtagene vicleucel (bb2121) JNJ-68284582 |
Anti-BCMA Anti-BCMA with dual epitope targeting |
150–450 × 10–6 0.75 × 10–6 |
Phase I: ORR 85%, median PFS: 11.8 mo Phase II: ORR 73%, median PFS 8.6 mo (11.3 mo in patients that received the 450 × 10–6 dose) Phase Ib/2: (CARTITUDE-1): ORR 100% (CR= 69%) |
CRS: Phase I: 76% (grade 3 ≥ 6%), median time to onset 2 days Phase II (84%, 5% grade 3) Neurotoxicity= 42% of patients (mostly grades 1 and 2) CRS: 93% (86% grades 1–2) Median time to onset: 7 days Neurotoxicity: 10% (grade 3 = 3%) |
| Bispecific T-Cell Engagers | AMG 420 AMG 701 CC-93269 |
Anti-BCMA Anti-BCMA Anti-BCMA |
Continuous infusion, 400 microgram/kg dose effective TBD, longer half-life Dose: 6–10mg: weekly, biweekly and then monthly |
ORR: 70% (at 400u/kg dose) N/A ORR: 88.9% (10mg dose) CR rate 44.4% |
CRS: 38%, polyneuropathy N/A CRS: 76.7% (3.3% grade 3 or greater) |
| Antibody Drug Conjugates | Belantamab mafodotin | Anti-BCMA, conjugated to MMAF | Dose: 2.5–3.4 mg/kg, every 3 weeks | Phase I (DREAMM-1): ORR 60% (3.4mg/kg dose) (Triple class refractory RR: 38.5%) Median PFS 12 months (triple class refractory = 6.2 mo) Phase II (DREAMM-2): ORR 34% (3.4mg/kd dose) ORR 31% (2.5mg/kg dose) |
Phase I: Keratopathy (27%), Phase II 54% (grade 1–2) |
Abbreviations: CRS, cytokine release syndrome; ORR, overall response rate; CR; complete response rate; PFS, progression free survival